Comparative Clinical Trial of Antibodies to Interferon-Gamma (IFN-γ) and Tumor Necrosis Factor-Alpha (TNF-α) in the Treatment of Rheumatoid Arthritis
Read full paper at:
http://www.scirp.org/journal/PaperInformation.aspx?PaperID=53325#.VL3BYizQrzE
Author(s)
http://www.scirp.org/journal/PaperInformation.aspx?PaperID=53325#.VL3BYizQrzE
Author(s)
Simon Skurkovich1*, Galina Lukina2, Yakov Sigidin2, Olga Pushkova2, Evelyna Mach2, Boris Skurkovich3
Affiliation(s)
1Advanced Biotherapy Laboratories, Rockville, USA.
2Institute of Rheumatology, Russian Academy of Medical Sciences, Moscow, Russia.
3Warren Alpert Medical School of Brown University, Providence, USA.
2Institute of Rheumatology, Russian Academy of Medical Sciences, Moscow, Russia.
3Warren Alpert Medical School of Brown University, Providence, USA.
ABSTRACT
In
1974, in Nature, one of us has proposed a radically new idea that led
to the development of anticytokine therapy which is now used around the
world for the treatment of autoimmune diseases. We were the first to use
antibodies to IFN-γ and were some of the first to suggest using
antagonists of TNF-α in the treatment of autoimmune and inflammatory
diseases as well. Our method suppresses one of the main pathogenetic
mechanisms of these diseases. Antibodies to IFN-γ and TNF-α exhibit
dramatic effects on clinical manifestations of rheumatoid arthritis
(RA). However, in our trial ultrasound assessment of the synovial
membrane thickness in RA patients showed that only anti-IFN-γ exerted
pronounced anti-inflammatory effect. Some patients who underwent
treatment with antibodies to TNF-α developed a number of complications.
Anticytokine therapy (mono- and poly-) alone or in combination with
other drugs can possibly be used not only in the treatment of autoimmune
diseases, but also in other pathologies with cytokine synthesis
disturbances (a number of neurological, psychiatric, endocrine, and
other diseases).
Cite this paper
References
Skurkovich,
S. , Lukina, G. , Sigidin, Y. , Pushkova, O. , Mach, E. and Skurkovich,
B. (2015) Comparative Clinical Trial of Antibodies to Interferon-Gamma
(IFN-γ) and Tumor Necrosis Factor-Alpha (TNF-α) in the Treatment of
Rheumatoid Arthritis. Journal of Immune Based Therapies, Vaccines and Antimicrobials, 4, 1-8. doi: 10.4236/jibtva.2015.41001.
| [1] | Skurkovich,
S.V., Klimova, K.G., Eremkina, E.I., et al. (1974) Immunosuppressive
Effect of an Anti-Interferon Serum. Nature, 247, 551-552. http://dx.doi.org/10.1038/247551a0 |
| [2] | Skurkovich, S.V. and Eremkina, E.I. (1975) Probable role of Interferon in Allergy. Annals of Allergy, 35, 356-360. |
| [3] | Skurkovich, S.V., Loukina, G.V., Sigidin, Y.A. and Skurkovich, B. (1998) Successful First-Time Use of Antibodies to Interferon-Gamma Alone and Combined with Antibodies to Tumor Necrosis Factor-Alfa to Treat Rheumatic Diseases (Rheumatoid Arthritis, Systemic Lupus Erythematosus, Psoriatic Arthritis, Behcet’s Syndrome). International Journal of Immunotherapy, 14, 23-32. |
| [4] | Sigidin,
Y.A., Loukina, G.V., Skurkovich, B. and Skurkovich, S. (2001)
Randomized, Double-Blind Trial of Anti-Interferon-γ Antibodies in
Rheumatoid Arthritis. Scandinavian Journal of Rheumatology, 30, 203-207.
http://dx.doi.org/10.1080/030097401316909530 |
| [5] | Skurkovich, S.V. and Skurkovich, B. (1989) Development of Autoimmune Diseases Is Connected with the Initial Disturbance of IFN Synthesis in the Cells. Journal of Intrerferon Research, 9, S305. |
| [6] | Elliott,
M.J., Maini, R.N. and Feldmann, M. (1994) Randomized Double-Blind
Comparison of Chimeric Monoclonal Antibody to Tumor Necrosis Factor
Alpha (cA2) versus Placebo in Rheumatoid Arthritis. Lancet, 344,
1105-1110. http://dx.doi.org/10.1016/S0140-6736(94)90628-9 |
| [7] | Skurkovich,
S., Skurkovich, B. and Bellanti, J.A. (1987) A Unifying Model of the
Immunoregulatory Role of the Interferon System: Can Interferon Produce
Disease in Humans? Clinical Immunology and Immunopathology, 43, 362-
373. http://dx.doi.org/10.1016/0090-1229(87)90146-2 |
| [8] | Vandana, T. and Bhupinder, S.K. (2007) Cytokines and Anti-Cytokines as Therapeutics—An Update. European Journal of Pharmacology, 579, 1-12. |
| [9] | Billiau, A. (1996) Interferon-γ in Autoimmunity. Cytokine & Growth Factor Reviews, 7, 25-34. http://dx.doi.org/10.1016/1359-6101(96)00004-4 |
| [10] | Dayer, J.M. (1992) Cytokines, Soluble Cytokine Receptors and Cytokine Receptor Antagonists. EULAR Bulletin, 21, 7-14. |
| [11] | Dolhain,
R.J.E.M., Ter Haar, N.T., Hoefakker, S., Tak, P.P., De Ley, M.,
Claassen, E., et al. (1996) Increased Expression of Interferon
(IFN)-Gamma Together with IFN-Gamma Receptor in the Rheumatoid Synovial
Membrane Compared with Synovium of Patients with Osteoarthritis. British
Journal of Rheumatology, 35, 24-32. http://dx.doi.org/10.1093/rheumatology/35.1.24 |
| [12] | Duff, G.W. (1994) Cytokines and Acute Phase Proteins in Rheumatoid Arthritis. Scandinavian Journal of Rheumatology, 23, 9-19. http://dx.doi.org/10.3109/03009749409095197 |
| [13] | Skurkovich,
S., Skurkovich, B. and Kelly, J. (2002) Anticytokine Therapy—New
Approach to the Treatment of Autoimmune and Cytokine-Disturbance
Diseases. Medical Hypotheses, 59, 770-780. http://dx.doi.org/10.1016/S0306-9877(02)00346-8 |
| [14] | German
Lymphokine Study Group (1992) Double Blind Controlled Phase III
Multicenter Clinical Trial with Interferon Gamma in Rheumatoid
Arthritis. Rheumatology International, 12, 175-185. http://dx.doi.org/10.1007/BF00302149 |
| [15] | Cannon, G.W., Emkey, R.D., Denes, A., Cohen, S.A., Saway, P.A., Wolfe, F., et al. (1993) Prospective 5-Year Follow-Up of Recombinant Interferon-Gamma in Rheumatoid Arthritis. The Journal of Rheumatology, 20, 1867-1873. |
| [16] | Veys, E. (1997) Interferon-Gamma in the Treatment of Rheumatoid Arthritis. In: Strand, V., et al., Eds., Novel Therapeutic Agents in the Treatment of Autoimmune Diseases, Marcel Dekker, Inc., New York. |
| [17] | Canete,
J.D., Martínez, S.E., Farrés, J., Sanmartí, R., Blay, M., Gómez, A., et
al. (2000) Differential Th1/Th2 Cytokine Patterns in Chronic Arthritis:
Interferon Gamma Is Highly Expressed in Synovium of Rheumatoid
Arthritis Compared with Seronegative Spondyloarthropathies. Annals of
the Rheumatic Diseases, 59, 263-268. http://dx.doi.org/10.1136/ard.59.4.263 |
| [18] | Koga, T., Duan, H., Urabe, K. and Furue, M. (2002) In Situ Localization of IFN-Gamma-Positive Cells in Psoriatic Lesional Epidermis. European Journal of Dermatology, 12, 20-23. |
| [19] | Sato-Kawamura, M., Aiba, S. and Tagami, H. (2003) Strong Expression of CD40, CD54 and HLA-DR Antigen and Lack of Evidence for Direct Cellular Cytotoxicity Are Unique Immunohistopathological Features in Alopecia Areata. Archives of Dermatological Research, 294, 536-543. |
| [20] | Skurkovich, S., Boiko, A., Beliaeva, I., Buglak, A., Alekseeva, T., Smirnova, N., et al. (2001) Randomized Study of Antibodies to IFN-γ and TNF-α in Secondary Progressive Multiple Sclerosis. Multiple Sclerosis, 7, 277-284. |
| [21] | Skurkovich, S.V., Volkov, I.E., Delyagin, V.M., Rumyantzev, A.G. and Skurkovich, B. (2003) First Use of Anti-Interferon (IFN)-g in the Treatment of Type I Diabetes in Children. Proceedings of the 8th International Workshop on Autoantibodies and Autoimmunity Conference, Berlin, 10-13 September 2003. |
| [22] | Skurkovich, S., Korotky, N., Sharova, N. and Skurkovich, B. (2002) Anti-Interferon-g to Treat Alopecia Areata, Psoriasis Vulgaris, Vitiligo, Pemphigus Vulgaris, and Epidermolysis Bullosa. Proceedings of the 5th Asia Pacific Congress of Allergology and Clinical Immunology (APCASI), Seoul, 12-15 October 2002, 121-125. |
| [23] | Skurkovich,
S., Kasparov, A., Narbut, N. and Skurkovich, B. (2002) Treatment of
Corneal Transplant Rejection in Humans with Anti-Interferon-γ
Antibodies. American Journal of Ophthalmology, 133, 136-137. http://dx.doi.org/10.1016/S0002-9394(02)01433-2 |
| [24] | Serono Announces Discontinuation of Onercept in Moderate-to Severe Psoriasis and Canvaxin TM in Stage IV Melanoma. http://www.prnewswire.com/news-releases/serono-announces-discontinuation-of-onercept-in-moderate-to-severe-psoriasis-and-canvaxintm-in-stage-iv-melanoma-66652342.html |
| [25] | Scheinfeld,
N. (2004) A Comprehensive Review and Evaluation of the Side Effects of
the Tumor Necrosis Factor Alpha Blockers Etanercept, Infliximab and
Adalimumab. Journal of Dermatological Treatment, 15, 280-294. http://dx.doi.org/10.1080/09546630410017275 eww150120lx |
评论
发表评论